Compare BridgeBio Pharma Inc (BBIO) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | PBW | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $46.99 |
52-Week Low | $47.29 | $23.73 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.
The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
